Mucin-based Targeted Pancreatic Cancer Therapy

Author(s): Maria P. Torres, Subhankar Chakraborty, Joshua Souchek, Surinder K. Batra

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 17 , 2012

Become EABM
Become Reviewer
Call for Editor


The prognosis of pancreatic cancer (PC) patients is very poor with a five-year survival of less than 5%. One of the major challenges in developing new therapies for PC is the lack of expression of specific markers by pancreatic tumor cells. Mucins are heavily Oglycosylated proteins characterized by the presence of short stretches of amino acid sequences repeated several times in tandem. The expression of several mucins including MUC1, MUC4, MUC5AC, and MUC16 is strongly upregulated in PC. Recent studies have also demonstrated a link between the aberrant expression and differential overexpression of mucin glycoproteins to the initiation, progression, and poor prognosis of the disease. These studies have led to increasing recognition of mucins as potential diagnostic markers and therapeutic targets in PC. In this focused review we present an overview of the therapies targeting mucins in PC, including immunotherapy (i.e. vaccines, antibodies, and radioimmunoconjugates), gene therapy, and other novel therapeutic strategies.

Keywords: Pancreatic cancer, mucins, targeted therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 22 April, 2012
Page: [2472 - 2481]
Pages: 10
DOI: 10.2174/13816128112092472
Price: $65

Article Metrics

PDF: 21